Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
European Journal of Medicinal Chemistry|May 19, 2017
2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitorsXueqiang Li, Christopher P Guise, Rana Taghipouran, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 29, 2005
Cancer chemotherapy and drug metabolismDavid S Riddick, Chunja Lee, Shairoz Ramji, et al.
Pharmaceuticals (Basel, Switzerland)|December 28, 2021
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3Maria R Abbattista, Amir Ashoorzadeh, Christopher P Guise, et al.
Molecular Cancer Therapeutics|December 8, 2011
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302Fanying Meng, James W Evans, Deepthi Bhupathi, et al.
Acta Pharmacologica Sinica|June 23, 2026
Development of XYD113 as a potent and highly selective GSPT1 degrader for cancer therapyHui Shen, Xiao-Yu Luo, Xin-Yi Jing, et al.
Biochemical Pharmacology|January 18, 2014
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cellsStephen M F Jamieson, Yongchuan Gu, Donya Moradi Manesh, et al.
Blood Cancer Journal|November 6, 2024
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemiaCara E Toscan, Hannah McCalmont, Amir Ashoorzadeh, et al.
Molecular Cancer Therapeutics|October 9, 2021
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506Alexander M A van der Wiel, Victoria Jackson-Patel, Raymon Niemans, et al.
Pageof 9